

# The Prevalence and Risk Factors of Osteoporosis among a Saudi Female Diabetic Population

Ibrahim Abdulrazag AL-Homood<sup>1</sup>, Iman Sheshah<sup>2</sup>, Abdel Gaffar A. Mohammed<sup>1\*</sup>, Gasim I. Gasim<sup>3</sup>

<sup>1</sup>Medical Specialties Department, Rheumatology Section, King Fahad Medical City, Riyadh, Saudi Arabia; <sup>2</sup>Diabetic Center, King Salman Hospital, Riyadh, Saudi Arabia; <sup>3</sup>Alneelain University, Faculty of Medicine and Health Sciences, Khartoum, Sudan

## Abstract

**Citation:** AL-Homood IA, Sheshah I, Mohammed AGA, Gasim GI. The Prevalence and Risk Factors of Osteoporosis among a Saudi Female Diabetic Population. Open Access Maced J Med Sci. 2017 Apr 15; 5(2):177-181. <https://doi.org/10.3889/oamjms.2017.030>

**Keywords:** osteoporosis; osteopenia; Saudi women; diabetes mellitus.

**\*Correspondence:** Abdel Gaffar A Mohammed. Medical specialties department, Rheumatology section, King Fahad Medical City, Riyadh, Saudi Arabia.P.O.Box 59046 Riyadh 11525. Tel. +966112889999. E-mail: aabdogafar@gmail.com

**Received:** 17-Dec-2016; **Revised:** 10-Feb-2017; **Accepted:** 12-Feb-2017; **Online first:** 08-Apr-2017

**Copyright:** © 2017 Ibrahim Abdulrazag AL-Homood, Iman Sheshah, Abdel Gaffar A. Mohammed, Gasim I. Gasim. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

**Funding:** This research did not receive any financial support.

**Competing Interests:** The authors have declared that no competing interests exist.

**AIM:** This study aimed to assess the prevalence and determinants of osteoporosis [lumbar spine (LS) and femoral neck (FN)] among patients with type 2 diabetes at King Salman Hospital.

**MATERIALS AND METHODS:** One hundred seventy patients with type 2 diabetes were enrolled in this cross-sectional study in the period from the 1st of January until the 1st of July 2015. Patient selection was based on self-report of the previous diagnosis by a physician, being on an antidiabetic agent, or a fasting glucose of 126 mg/dl as per the American Diabetes Association criteria. A dual energy X-ray absorptiometry scan with the bone mineral density (BMD) categorization based on the WHO cut of levels of T-scores and determination of vitamin D levels were performed. A detailed questionnaire was used to collect demographic data.

**RESULTS:** Out of 170 participants, 50 (29.4%) were diagnosed as having osteoporosis, while 68 (40%) were diagnosed with osteopenia. Age was determined as a risk factor for a decreased BMD in patients with osteopenia (odds ratio (OR) = 1.1, 95% confidence interval (CI) = (1.0-1.1),  $p = 0.039$ ) and osteoporosis (OR = 1.1, CI = 1.0-1.2,  $p < 0.001$ ). Similarly, oral hypoglycemic agents (OHA) increased the risk of decreased BMD in osteopenia (OR = 2.6; CI = 1.0-6.7;  $p = 0.023$ ) as well as osteoporosis, (OR = 3.8; CI = 1.3-10.9;  $p = 0.013$ ), while vitamin D deficiency increased the risk of osteopenia OR = 3.0; CI = 1.2-7.2;  $p = 0.012$ ). Increased BMI decreased the risk of both osteopenia and osteoporosis (OR = 0.9; CI = 0.9-0.99;  $p = 0.031$  vs. OR = 0.9; CI = 0.80-0.95;  $p = 0.003$ ).

**CONCLUSION:** Advanced age, OHA and vitamin D deficiency are determinants of decreased BMD in Saudi women with type 2 diabetes, while an increased BMI protects against low BMD.

## Introduction

Diabetes mellitus has become a major problem worldwide, and it is speculated that the burden of such a problem will reach 7.7% by the year 2030 [1]. The Arabian Gulf area is one of the most affected regions where the problem of obesity is expected to continue to rise, and five of the region states are likely to be among the ten countries with the highest diabetic morbidity by the year 2030 [1, 2]. Reports about the prevalence of diabetes mellitus in Saudi Arabia estimate the current prevalence to be around 17% with expectations that it will peak at more than 20% by the year 2030 [3].

Osteoporosis is defined by the presence of both reduced bone mass and altered bone quality, along with micro-architectural abnormalities, leading

to decreased bone strength and probably pathological fractures [4]. The risk factors for osteoporosis include advanced age, use of glucocorticoids, nutritional factors, low body mass index and genetic factors [5-7]. According to a recent report, more than one-third of the healthy Saudi individuals were found to have osteoporosis [8].

Despite the presence of different reports describing skeletal disorders among patients with diabetes, controversy remains concerning the risk of osteoporosis and its clinical importance among these patients [9]. Some studies have shown osteopenia and frequent bone fractures among type 1 diabetics; nonetheless, evidence demonstrating this risk among type 2 diabetics remains elusive [10,11]. Evidence of high bone mineral density and body mass index (BMI) shown in previous epidemiological studies proposing a reduction in fracture risk led to the assumption that

type 2 diabetics could have a lower risk of osteoporosis [12]. However, recent evidence suggests that the fracture risk among patients with type 2 diabetes is higher, whether high bone mineral density (BMD) is present or not [10, 13]. Both type 1 and 2 diabetes mellitus is regarded as a risk factor within the Fracture Risk Assessment Tool (FRAX-algorithm), which is commonly used to examine the probability of fracture [14].

The coexistence of osteoporosis and type 2 diabetes mellitus is common among the elderly population, putting this group at higher risk of bone fracture. Additional investigations are desirable to explore possible risk factors and predictors of osteoporosis among elderly.

The aim of the current study was to assess the prevalence and of risk factors for osteoporosis (lumbar spine (LS) and femoral neck (FN) BMD < -2.5 SD T-score) in a cohort of consecutive female patients with type 2 diabetes mellitus.

## Patients and Methods

### Patients

This is a cross-sectional study where we included a total number of 170 females with type 2 diabetes. The patients were recruited consecutively from the outpatient clinic of King Salman Hospital, Riyadh, Saudi Arabia after obtaining their consent. Data was gathered using a structured questionnaire during the follow-up visits for the control of diabetes between the 1<sup>st</sup> of January until the 1<sup>st</sup> of July 2015. The questionnaire included the patients' demographic data, history of comorbidities, medicaments history including vitamin D supplementation and the anti-diabetic agents along with an evaluation of proposed osteoporosis risk factors such as the history of immobility, exercise, and previous fragility fracture.

### Methods

The diagnosis of type 2 diabetes was based on reviewing the patients' outpatient clinic medical records of the Department of Internal Medicine, Endocrinology, at King Salman Hospital. The sample size was calculated using the Epi- info statistical calculator utilising the formula

$$\text{Sample size } n = \frac{[DEFF * Np(1-p)]}{[(d^2 / Z^2_{1-\alpha/2} * (N-1) + p * (1-p))]} = 167$$

We used a population size (for finite population correction factor or fpc) (N):1000000, and we assumed that the prevalence of the disease among the Saudi population is 34% based on previous publications, and we calculated our sample

size with 5% limit of confidence and an 80% study power.

Diabetes was considered based on self-report of diabetes previously diagnosed by a physician in the medical records, if the patient was already taking antidiabetic medication or by obtaining a fasting glucose reading of 126 mg/dl as per the American Diabetes Association criteria [16]. Patients presenting with type 1 diabetes mellitus were excluded from the study. Measurement of BMD was carried at the LS (L2–L4, LS) and the right and left femur necks using dual-energy x-ray absorptiometry (DXA) by a Hologic 4500 bone densitometer. We compared our patient's measurements with age- and sex-matched normal reference values provided by Hologic for Caucasian populations. BMD categorization was based on the cut-off levels of T-scores set by the WHO [where osteoporosis is diagnosed as a (T-score < -2.5 SD), osteopenia (T-score from -1 to -2.5 SD) and normal (t-score > -1 SD)] [17].

### Ethical approval

Ethical approval for the current study was obtained from the Ethics Committee of King Fahad Medical city. All participants and patients were enrolled in the study after signing a written informed consent.

### Statistical analysis

SPSS for Windows (version 20.0) was used for analysis after data were entered into computer database. To compare the continuous variables (after checking for normality and proportions between the different groups of BMD), one –way ANOVA was used as well as  $\chi^2$  tests. Multinomial logistic regression was used when the p value of variables of the one-way ANOVA and  $\chi^2$  test were less than < 0.2, with BMD groups entered as the dependent variables and age, body mass index (BMI), history of previous fragility fracture, vitamin D deficiency, history of type 2 diabetes mellitus and use of oral hypoglycemic agents as independent variables. On calculating the odds ratios and 95 % confidence interval, a p value was regarded significant if it is < 0.05.

## Results

The general characteristics of the 170 participants are shown in Table 1. Around one-third (29.4%) of our patients were found to have osteoporosis, while 68(40%) of the enrolled women were found to have osteopenia.

**Table 1: Showing the characteristics of the study population**

Variable	N = 170 and %
Age in years (mean ± SD)	56.3 ± 8.5
BMI (mean ± SD)	32.2 ± 6.2
Insulin	27 ± 19%
Oral Hypoglycaemics	85 ± 59.9%
Osteoporosis	50 ± 29.4%
Osteopenia	68 ± 40%
Immobilty	3 ± 1.8
Exercise	17 ± 10%
Myopathy	18 ± 10.6%
Use of steroids	1 ± 0.6%
Use of Calcium	86 ± 50.6%
Estrogen deficiency	29 ± 17.1%
Smoking	2 ± 1.2%
Early menopause	9 ± 5.3%
Alcohol	0
Rheumatoid Arthritis	0
Vitamin D supplement	84 ± 49.4%
Kyphosis	3 ± 1.8%
Frax score	116 ± 68.2%
Low	34 ± 20%
Moderate	20 ± 11.8%
High	

Out of the enrolled 170 women, 116 (68.2%) scored low FRAX index, 34 (20%) had intermediate and 20 (11.8%) women a high FRAX index score. Use of oral hypoglycemic medication was confirmed in 59.9% of patients. The prevalence of osteoporosis based on location is shown in Table 2. The comparison regarding the prevalence of osteoporosis between the different groups shows that it is detected more frequently on examining the vertebrae (28%).

**Table 2: Prevalence of osteopenia and osteoporosis in postmenopausal diabetic Saudi women according to bone mineral density and WHO criteria**

Variable	Normal n (%)	Osteopenia n (%)	Osteoporosis n (%)
Vertebrae	56 (32.9)	66 (38.8)	48 (28.3)
Right femur	114 (67.1)	50 (29.4)	6 (3.5)
Left Femur	115 (67.6)	49 (28.8)	6 (3.5)

While there was no significant difference in the distribution of cases who are on insulin, immobile, those who were exercising, or suffering myopathy, the age, the prior history of fragility fracture, use of oral hypoglycemic agents and vitamin D deficiency were significantly higher in the osteoporosis group compared to the group with normal BMD reflecting that they were risk factors for low BMD. To the contrary, BMD was found to decrease with reductions in BMI (see Table 3).

**Table 3: Univariate analysis comparing the characteristics of the study population, between the bone mineral density groups among Saudi women**

Variables	Normal (52)	P value	Osteopenia N (68)	P value	Osteoporosis N (50)	P value
Age in years (mean(sd))	52.3 (7)	0.034	56.2 (7.5)	0.050	60.5 (9.2)	<0.001
BMI(mean(sd))	34.2 (6)	0.040	32.1 (6.1)	0.129	30.2 (6.2)	0.005
Insulin	5	0.351	13	0.110	9	0.278
Oral Hypoglycaemics	33	0.018	34	0.015	18	0.038
Immobilty	1	1.000	0	*	2	0.263
Exercise	3	0.872	7	0.475	7	0.381
Myopathy	5	0.093	6	0.762	7	0.641
Vitamin D deficiency	31	0.010	24	0.012	29	0.011
Calcium intake	24	0.015	40	0.012	22	0.010
Use of steroids	0	0.145	0	*	1	0.292
Early Menopause	0	0.999	5	<0.001	4	0.140
Caffeine	15	0.562	0	0.337	0	0.499

\*This parameter is set to zero because it is redundant.

Multinomial analyses (Table 4) showed that age was a risk factor for a decreased BMD for both osteopenia (odds ratio (OR) = 1.1, 95% confidence interval (CI) = (1.0-1.1), p = 0.039) and osteoporosis (1.1) (1.0-1.2), p = <0.001). Similarly use of oral hypoglycemic agents increased the risk of decreased BMD in cases with osteopenia (2.6) (1.0-6.7), p = 0.032) as well as with osteoporosis, (3.8) (1.3-10.9), p = 0.013), while vitamin D deficiency increased the risk of osteopenia alone (3.0) (1.3-7.2), p = 0.012).

**Table 4: The Odds ratio (95% confidence interval), P value for multinomial analyses where normal bone mineral density was the reference**

Variables	Osteopenia (N = 91)			Osteoporosis (N = 55)				
	OR	CI	P value	OR	CI	P value		
Age in years (mean ± sd)	56.2 ± 7.5	1.1	1.0-1.13	0.039	60.5 ± 9.2	1.1	1.0-1.2	<0.001
BMI (mean ± sd)	32.1 ± 6.1	0.9	0.9-0.99	0.031	30.2 ± 6.2	0.9	0.80-0.95	0.003
Oral Hypoglycaemics	34	2.6	1.0-6.7	0.023	18	3.8	1.3-10.9	0.013
Vitamin D deficiency	24	3.0	1.2-7.2	0.012	29	1.5	0.5-3.9	0.502

Calcium was set to zero because it was redundant. On the other side high BMI decreased the risk of both osteopenia and osteoporosis (0.9) (0.9-0.99), p = 0.031, 0.9 (0.79-0.95), p = 0.003 respectively.

## Discussion

The prevalence of osteoporosis among the diabetic population we studied was 29.4%, which is slightly less than what was previously reported in Saudi Arabia (34%) [8]. This could be explained in the context of what has been described by Vestergaard in his study which showed that patients with type 2 diabetes tend to have a higher BMD. Nonetheless, they have a higher fracture risk [18]. Another important finding reflected by the current study is the agreed upon fact regarding the inverse relation between age and BMD in cases of osteopenia and osteoporosis [19-21] which is likely attributed to the mobilization of calcium from bone. According to the present study, the advancement in age increased the likelihood of osteopenia and osteoporosis with an odds-ratio of 1.1. An explanation for this weak effect is the background of our patients since it is believed that type 2 diabetes is associated with a higher BMD as has been mentioned before. The use of oral hypoglycemic agents was another predictor for the development of osteopenia or osteoporosis as indicated by the current study. Based on our findings, patients on oral hypoglycemic medications have a nearly three times risk of developing osteopenia and more than four times chance of becoming osteoporotic. These findings are in agreement with what was demonstrated by Billington et al. in their

meta-analysis regarding the effects of thiazolidinediones on BMD [22]. Moreover, it is known that metformin is associated with a higher incidence of bone fractures [23]. It is worth mentioning that our results included oral hypoglycemic agents with no reference to a particular type of the oral hypoglycemic agents. Kumar et al. found that oral hypoglycemic agents did not affect the BMD after usage for three years [24]. The current study showed that BMI protects against a decrease in BMD, such a finding has been claimed by Chen et al. in their study among elderly type 2 diabetic men [25], nonetheless, other researchers declared different findings concerning the relation between BMI and BMD [26].

Expectedly, vitamin D deficiency decreased BMD in diabetic patients we studied, as has been previously shown in another study [27]. In contrast to our findings, Kota et al. found no direct relation between Vitamin D levels and BMD despite showing a significant association with the parathormone levels [28]. However, the effect of vitamin D deficiency was seen in osteopenic patients only, a finding that might be explained by supplementation of some of the osteoporotic patients with vitamin D preparations. We have to acknowledge the fact that more details about the hypoglycemic agents would have led to better conclusions. Including controls would have helped to delineate the type 2 diabetes risk of osteoporosis. One more important limitation to our study is the fact that it has been conducted among a female population and thus it is difficult to extrapolate our results to the whole community.

In conclusion, the current study showed that advanced age, oral hypoglycemic agents and vitamin D deficiency are risk factors for a decreased bone mineral density, while an increased BMI was found to guard against a reduction in BMD in Saudi women. A case-control study on a larger scale is recommended and is expected to describe the risk factors and the relation between type 2 diabetes and osteoporosis in a more clear way.

## References

- Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract.* 2010;87:4-14. <https://doi.org/10.1016/j.diabres.2009.10.007> PMID:19896746
- Alhyas L, McKay A, Majeed A. Prevalence of Type 2 Diabetes in the States of the Co-Operation Council for the Arab States of the Gulf: A Systematic Review. Sesti G, ed. *PLoS ONE.* 2012;7:e40948.
- Al-Quwaidhi AJ, Pearce MS, Sobngwi E, Critchley JA, O'Flaherty M. Comparison of type 2 diabetes prevalence estimates in Saudi Arabia from a validated Markov model against the International Diabetes Federation and other modelling studies. *Diabetes Research and Clinical Practice.* 2014;103:496-503. <https://doi.org/10.1016/j.diabres.2013.12.036> PMID:24447810 PMCid:PMC4013554
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy, "Osteoporosis prevention, diagnosis and therapy," *The Journal of the American Medical Association.* 2001;285:785-795. <https://doi.org/10.1001/jama.285.6.785> PMID:11176917
- Zhang X, Lin J, Yang X, Wang B, Yang Y, Li J et al. [Investigation of osteoporosis prevalence and osteoporosis-related clinical risk factors among healthy elderly male]. *Zhonghua Yi Xue Za Zhi.* 2015;95:3366-9. PMID:26812978
- Carli L, Tani C, Spera V, Vagelli R, Vagnani S, Mazzantini M et al. Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. *Lupus Science & Medicine.* 2016;3:e000098. <https://doi.org/10.1136/lupus-2015-000098> PMID:26848397 PMCid:PMC4731833
- Sarkis KS, Salvador MB, Pinheiro MM, Silva RG, Zerbini CA, Martini LA. Association between osteoporosis and rheumatoid arthritis in women: a cross-sectional study. *Sao Paulo Med J.* 2009;127:216-22. <https://doi.org/10.1590/S1516-31802009000400007> PMID:20011927
- Alwahabi BK. Osteoporosis in Saudi Arabia: Are we doing enough? *Saudi Medical Journal.* 2015;36:1149-1150. <https://doi.org/10.15537/smj.2015.10.11939> PMID:26446322 PMCid:PMC4621717
- Jackuliak P, Payer J. Osteoporosis, fractures, and diabetes. *Int J Endocrinol.* 2014;820615. <https://doi.org/10.1155/2014/820615>
- Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. *Am J Epidemiol.* 2007;166:495-505. <https://doi.org/10.1093/aje/kwm106> PMID:17575306
- Mastrandrea LD, Wactawski-Wende J, Donahue RP, Hovey KM, Clark A, Quattrin T. Young women with type 1 diabetes have lower bone mineral density that persists over time. *Diabetes Care.* 2008;31:1729-35. <https://doi.org/10.2337/dc07-2426> PMID:18591404 PMCid:PMC2518333
- Saito M, Marumo K. Bone Quality in Diabetes. *Frontiers in Endocrinology.* 2013;4:72. <https://doi.org/10.3389/fendo.2013.00072> PMID:23785354 PMCid:PMC3682213
- deLiefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. *Osteoporos Int.* 2005;16:1713-1720. <https://doi.org/10.1007/s00198-005-1909-1> PMID:15940395
- Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. *Osteoporos Int.* 2008;19:385-397. <https://doi.org/10.1007/s00198-007-0543-5> PMID:18292978 PMCid:PMC2267485
- Mathen PG, Thabab MM, Zachariah B, Das AK. Decreased Bone Mineral Density at the Femoral Neck and Lumbar Spine in South Indian Patients with Type 2 Diabetes. *JCDR.* 2015; 9:OC08-OC12. <https://doi.org/10.7860/jcdr/2015/14390.6450>
- American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care.* 2010;33:S62-S69. <https://doi.org/10.2337/dc10-S062> PMID:20042775 PMCid:PMC2797383
- Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. *Lancet.* 2002;359:1929-1936. [https://doi.org/10.1016/S0140-6736\(02\)08761-5](https://doi.org/10.1016/S0140-6736(02)08761-5)
- Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. *Osteoporos Int.* 2007;18:427-44. <https://doi.org/10.1007/s00198-006-0253-4> PMID:17068657
- Lo SS. Bone health status of postmenopausal Chinese women. *Hong Kong Med J.* 2015;21:536-41. PMID:26492837
- Lin LP, Hsu SW, Yao CH, et al. Risk for osteopenia and osteoporosis in institution-dwelling individuals with intellectual and/or developmental disabilities. *Res Dev Disabil.* 2014;36C:108-

113. PMID:25462471
21. Betancourt Ortiz SL. [Bone mineral density, dietary calcium and risk factor for presumptive osteoporosis in Ecuadorian aged women]. *Nutr Hosp*. 2014;30:372-84. PMID:25208793
22. Billington EO, Grey A, Bolland MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. *Diabetologia*. 2015; 58:2238-46. <https://doi.org/10.1007/s00125-015-3660-2> PMID:26109213
23. Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients. *Diabetes Care*. 2008; 31 : 199–203. <https://doi.org/10.2337/dc07-1736> PMID:18024851
24. Kumar BS, Ravisankar A, Mohan A, Kumar DP, Katyarmal DT, Sachan A, et al. Effect of oral hypoglycaemic agents on bone metabolism in patients with type 2 diabetes mellitus & occurrence of osteoporosis. *Indian J Med Res*. 2015;141:431-7. <https://doi.org/10.4103/0971-5916.159287> PMID:26112844 PMID:PMC4510723
25. Chen H, Deng L, Li J. Prevalence of Osteoporosis and Its Associated Factors among Older Men with Type 2 Diabetes. *International Journal of Endocrinology*. 2013:285729. <https://doi.org/10.1155/2013/285729>
26. Heaney RP, Barger-Lux MJ, Davies KM, Ryan RA, Johnson ML, Gong G. Bone dimensional change with age: interactions of genetic, hormonal, and body size variables. *Osteoporos Int*. 1999;7:426–31. <https://doi.org/10.1007/PL00004150>
27. Sunyecz JA. The use of calcium and vitamin D in the management of osteoporosis. *Therapeutics and Clinical Risk Management*. 2008; 4:827-836. <https://doi.org/10.2147/TCRM.S3552> PMID:19209265 PMID:PMC2621390
28. Kota S, Jammula S, Kota S, Meher L, Modi K. Correlation of vitamin D, bone mineral density and parathyroid hormone levels in adults with low bone density. *Indian Journal of Orthopaedics*. 2013;47:402-407. <https://doi.org/10.4103/0019-5413.114932> PMID:23960286 PMID:PMC3745696